Image-guided robotic radiosurgery as salvage therapy for locally recurrent prostate cancer after external beam irradiation: retrospective feasibility study on six cases

被引:42
作者
Vavassori, Andrea [1 ]
Jereczek-Fossa, Barbara Alicja [1 ,4 ]
Beltramo, Giancarlo [2 ]
De Cicco, Luigi [1 ]
Fariselli, Laura [6 ]
Bianchi, Livia Corinna [2 ]
Possanzini, Marco [2 ]
Bergantin, Achille [3 ]
DeCobelli, Ottavio [4 ,5 ]
Orecchia, Roberto [1 ,4 ]
机构
[1] European Inst Oncol, Dept Radiotherapy, I-20141 Milan, Italy
[2] Ctr Diagnost Italiano, Dept Radiotherapy, Milan, Italy
[3] Ctr Diagnost Italiano, Dept Med Phys, CyberKnife Unit, Milan, Italy
[4] Univ Milan, Milan, Italy
[5] European Inst Oncol, Dept Urol, I-20141 Milan, Italy
[6] C Besta Neurol Inst Fdn, Radiotherapy Unit, Milan, Italy
来源
TUMORI JOURNAL | 2010年 / 96卷 / 01期
关键词
CyberKnife; prostate cancer; reirradiation; salvage therapy; DOSE-RATE BRACHYTHERAPY; RADIATION-THERAPY; RADICAL PROSTATECTOMY; BIOCHEMICAL FAILURE; DOUBLING TIME; RADIOTHERAPY; ALPHA/BETA; MANAGEMENT; TOXICITY; ONCOLOGY;
D O I
10.1177/030089161009600112
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims and background. Technological advances in treatment planning and execution are providing new potential opportunities in the treatment of recurrent prostate cancer. This study was conducted to evaluate the feasibility and safety of reirradiation with image-guided radiosurgery using CyberKnife, a robotic, arm-driven compact linear accelerator, for intraprostatic recurrence after external beam radiotherapy (EMIT). Methods. Between September 2007 and May 2008, 6 patients diagnosed with locally recurrent prostate cancer after EBRT were treated using the CyberKnife system. The total reirradiation dose was 30 Gy in five fractions. Prior to radiosurgery four patients were treated with androgen-deprivation therapy. Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria and the Houston-Phoenix definition (PSA nadir + 2 ng/mL) were used for toxicity and biochemical failure evaluation, respectively. Results. After a median follow-up of 11.2 months (range, 9.6-18.6 months), all patients are alive with no evidence of severe urinary or rectal acute morbidity. Local control cannot be exactly determined due to the short follow-up and the bias of the use of androgen ablation. Four patients had biochemical failure, three of them with clinical failure evidence (lymph node, bone and lung metastasis, respectively): none of these patients had clinical evidence of tumor persistence in the prostate. Conclusions. Salvage radiosurgery with CyberKnife after irradiation is feasible with low urinary and rectal morbidity. A longer follow-up and a larger number of patients are necessary to evaluate its effectiveness and optimal patient selection criteria. Free full text available at www.tumorionline.it
引用
收藏
页码:71 / 75
页数:5
相关论文
共 40 条
  • [1] Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option
    Allen, Gregory W.
    Howard, Andrew R.
    Jarrard, David F.
    Ritter, Mark A.
    [J]. CANCER, 2007, 110 (07) : 1405 - 1416
  • [2] A review of 3 current radiosurgery systems
    Andrews, David W.
    Bednarz, Greg
    Evans, James J.
    Downes, Beverly
    [J]. SURGICAL NEUROLOGY, 2006, 66 (06): : 559 - 564
  • [3] [Anonymous], 2016, COMPR CANC NETW
  • [4] Long-term oncologic results of salvage radical prostatectomy for locally recurrent prostate cancer after radiotherapy
    Bianco, FJ
    Scardino, PT
    Stephenson, AJ
    DiBlasio, CJ
    Fearn, PA
    Eastham, JA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 62 (02): : 448 - 453
  • [5] CyberKnife® robotic stereotactic radiotherapy:: technical aspects and medical indications
    Bondiau, P. -Y.
    Benezery, K.
    Beckendorf, V.
    Peiffert, D.
    Gerard, J. -P
    Mirabel, X.
    Noel, A.
    Marchesi, V.
    Lacornerie, T.
    Dubus, F.
    Sarrazin, T.
    Herault, J.
    Marcie, S.
    Angellier, G.
    Lartigau, E.
    [J]. CANCER RADIOTHERAPIE, 2007, 11 (6-7): : 338 - 344
  • [6] Brenner DJ, 2002, INT J RADIAT ONCOL, V52, P6
  • [7] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC)
    COX, JD
    STETZ, J
    PAJAK, TF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05): : 1341 - 1346
  • [8] Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
    D'Amico, AV
    Moul, JW
    Carroll, PR
    Sun, L
    Lubeck, D
    Chen, MH
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (18) : 1376 - 1383
  • [9] Is the α/β value for prostate tumours low enough to be safely used in clinical trials?
    Dasu, A.
    [J]. CLINICAL ONCOLOGY, 2007, 19 (05) : 289 - 301
  • [10] 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer
    de Jong, IJ
    Pruim, J
    Elsinga, PH
    Vaalburg, W
    Mensink, HJA
    [J]. EUROPEAN UROLOGY, 2003, 44 (01) : 32 - 38